Last update June 22, 2022
Antiprogestin which derives from Norethisterone, Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome and to terminate pregnancies up to 50-70 days' gestation.
Its high plasma protein-binding capacity and large volume of distribution (Sarkar 2002) explains that excretion into breast milk is clinically non-significant. It achieves very low levels in breast milk at a maternal dose of 600 mg or undetectable at maternal dose of 200 mg. (Sääv 2010)
The punctual use of mifepristone does not contraindicate breastfeeding. (LactMed, Bettahar 2016)
When used with semi-experimental purposes due to its anti-androgenic and antiglucocorticoid properties a continuous administration and / or large doses is required. There is no experience in connection with breastfeeding. Those pathologies in which it is often used on a continuous basis by themselves are not compatible with breastfeeding.
We do not have alternatives for Mifepristone.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM